Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIP152 Monotherapy or Combination in High-risk CLL or Richter Syndrome
NCT04978779Phase 1Terminated
- Sponsor
- Vincerx
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of enitociclib in chronic lymphocytic leukemia (CLL) and Richter syndrome (RS) (2 arms), sponsored by Vincerx. Primary endpoint: Safety and Tolerability up to 3 years. Started Dec 2021; status: terminated.
02
Drugs
enitociclib
03
Conditions
chronic lymphocytic leukemia (CLL)Richter syndrome (RS)
Beyond the preview
Go deeper on NCT04978779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978779.